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AbsTrACT
background Within a surveillance of the prevalence 
and causes of vision impairment in high-income regions 
and Central/Eastern Europe, we update figures through 
2015 and forecast expected values in 2020.
Methods Based on a systematic review of medical 
literature, prevalence of blindness, moderate and severe 
vision impairment (MSVI), mild vision impairment and 
presbyopia was estimated for 1990, 2010, 2015, and 
2020.
results Age-standardised prevalence of blindness and 
MSVI for all ages decreased from 1990 to 2015 from 
0.26% (0.10–0.46) to 0.15% (0.06–0.26) and from 
1.74% (0.76–2.94) to 1.27% (0.55–2.17), respectively. 
In 2015, the number of individuals affected by blindness, 
MSVI and mild vision impairment ranged from 70 000, 
630 000 and 610 000, respectively, in Australasia to 980 
000, 7.46 million and 7.25 million, respectively, in North 
America and 1.16 million, 9.61 million and 9.47 million, 
respectively, in Western Europe. In 2015, cataract was 
the most common cause for blindness, followed by 
age-related macular degeneration (AMD), glaucoma, 
uncorrected refractive error, diabetic retinopathy and 
cornea-related disorders, with declining burden from 
cataract and AMD over time. Uncorrected refractive error 
was the leading cause of MSVI.
Conclusions While continuing to advance control of 
cataract and AMD as the leading causes of blindness 
remains a high priority, overcoming barriers to uptake of 
refractive error services would address approximately half 
of the MSVI burden. New data on burden of presbyopia 
identify this entity as an important public health 
problem in this population. Additional research on better 
treatments, better implementation with existing tools 
and ongoing surveillance of the problem is needed.
InTroduCTIon
Vision impairment is of great importance for quality 
of life and for the socioeconomics and public health 
of societies and countries. In the recent Global 
Burden of Disease Study (GBD) 2015, sense organ 
deficits including vision impairment and hearing 
impairment ranked second after low back and neck 
pain and before depressive disorders among the 
all-age causes for years lived with disability (YLDs) 
worldwide.1 Within the population aged 65+ years, 
sense organ deficits were the most common causes 
for YLDs. In a previous meta-analysis including 
data and results of most of the up-to-then available 
population-based studies in ophthalmology world-
wide, 32.4 million people were blind (defined as 
presenting visual acuity <3/60 in the better eye) 
in 2010, and 191 million people had a moderate 
and severe vision impairment (MSVI; defined as 
presenting visual acuity <6/18 but ≥3/60 in the 
better eye).2 The corresponding figures for the 
high-income countries and for Eastern and Central 
Europe were 2.736 million individuals blind 
(473 000 in high-income North America; 956 000 
in Western Europe) and 22.176 million individuals 
visually impaired (3.102 million in North America; 
7.490 million in Western Europe).3 The most 
common causes for blindness and vision impair-
ment worldwide were by far cataract and under-
correction of refractive error, whereas glaucoma, 
macular degeneration, diabetic retinopathy and 
other causes altogether included less than 25% of 
all causes.3 The burden of presbyopia has not been 
assessed.
Since surveillance of changes in public health 
parameters is needed to better analyse the effect 
of recent public health measures and to better 
allocate financial means for further improvement 
in public health, the Vision Loss Expert Group 
of the GBD Study has undertaken to monitor the 
status of visual impairment and blindness in the 
heterogeneous parts of the world every 5 years. We 
performed the current analysis to update the infor-
mation on blindness and vision impairment and its 
causes in the high-income countries and Eastern and 
Central Europe. Important changes in the countries 
in Eastern and Central Europe have included rapid 
economic development and large-scale migration 
of middle-aged individuals to Western European 
countries. Key novel features of this 2015 regional 
burden of visual impairment update include use 
of an improved statistical model, incorporation 
of more data sources, estimation of the burden of 
presbyopia and projections of numbers of people 
affected by distance vision impairment burden 
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to 2020, an important milestone year from a health-policy 
perspective.
MeThods
The methodology used for the preparation of prevalence esti-
mates for vision impairment and blindness, which includes 
a Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist, PRISMA flow sheet and 
a detailed account of the statistical models used, has been 
published in full elsewhere.4–6 A brief overview is given as 
follows. The study was approved by the ethics committee II of 
the Medical Faculty Mannheim of the University of Heidelberg, 
Germany. Using data in the Global Vision Database, we esti-
mated 1990–2015 trends in vision impairment prevalence and 
their uncertainties, by age and gender, for 188 countries in the 
21 GBD regions.7 The super region of ‘high-income countries, 
Eastern and Central Europe’ addressed in this report consists 
of the regions of Asia-Pacific, Australasia, North America high 
income, Western Europe, Central Europe and Eastern Europe. 
The distribution of countries within these regions is presented 
in table 1.
Using definitions and an analytical framework similar to that 
applied by Stevens and colleagues, we used statistical models to 
estimate the prevalence of two of the core categories of vision 
impairment: blindness, defined as presenting visual acuity worse 
than 3/60 in the better eye, and MSVI, defined as presenting 
visual acuity in the better eye of worse than 6/18 to 3/60 inclu-
sive. For the process of identification, access and extraction 
of data, we included data on distance vision impairment from 
population-based studies as identified through a systematic 
review.2–4 Mild vision impairment was defined as presenting 
visual acuity in the better eye of worse than 6/12 to 6/18 inclu-
sive. This review included investigations which were published 
between 1980 and July 2014. Additionally, we assessed unpub-
lished data which were identified by members of the Vision Loss 
Expert Group of the GBD Study.8 In total, nine new studies were 
added to the Global Vision Database for the high-income coun-
tries, Eastern and Central Europe super region, giving a total of 
46 studies contributing data from 22 countries.
For the statistical analysis, we fitted two hierarchical Bayesian 
logistic regressions to estimate vision impairment prevalence over 
time–by age group, gender and country–one model for the prev-
alence of blindness and one model for the prevalence of MSVI.9 
We modelled hierarchical linear trends over time, allowing for 
region-specific trends in prevalence of vision impairment in 
the seven world regions. Prevalence estimates were reported as 
posterior means along with 80% posterior uncertainty intervals 
(UIs).5 We calculated trends, with UIs, of age-standardised vision 
impairment by calculating the difference between the 1990 and 
2015 age-standardised prevalence.
In order to estimate the prevalence of presenting near vision 
impairment due to uncorrected presbyopia (functional pres-
byopia), we included studies where presbyopia was defined as 
presenting near vision worse than N6 or N8 at 40 cm regard-
less of distance refractive status. For broad estimates of vision 
impairment including both distance and near presenting impair-
ment, we only included data from those people whose best-cor-
rected visual acuity was 6/12 (20/40) or better, so as to avoid 
double counting those with both distance and near vision 
impairment associated with non-refractive causes. We developed 
a similar model to the main model used for blindness and MSVI. 
For the high-income countries, Eastern and Central Europe 
super region, there were three subnational sources of presbyopia 
prevalence used in the analysis, one from the USA, one from 
Australia and another from Canada.10–13
To forecast the prevalence of blindness and vision impairment 
to 2020, we applied our model to forecast prevalence of blind-
ness and MSVI into the future using United Nations Population 
Table 1 Countries included in the category of ‘high-income 
countries, Eastern and Central Europe’
Asia-Pacific (n=7) Brunei Darussalam, Japan* (n=3, 0), Republic of Korea* (n=2, 
2), Singapore* (n=2, 0)
Australasia (n=7) Australia* (n=7, 0), New Zealand
North America, high 
income (n=4)
Canada, USA* (n=4, 0)
Latin America, 
Southern (n=4)
Argentina* (n=1, 0), Chile* (n=2, 0), Uruguay* (n=1, 0)
Western Europe 
(n=20)
Andorra, Austria, Belgium, Cyprus, Denmark* (n=1, 0), Finland 
(n=1, 0), France (n=1, 0), Germany, Greece (n=1, 0), Iceland* 
(n=1, 0), Ireland, Israel, Italy* (n=3, 0), Luxembourg, Malta, 
Netherlands* (n=2, 0), Norway* (n=3, 2), Portugal, Spain* 
(n=2, 0), Sweden, Switzerland, UK* (n=5, 0)
Central Europe (n=1) Albania, Bosnia and Herzegovina, Bulgaria* (n=1, 0), Croatia, 
Czech Republic, Hungary, Montenegro, Poland, Romania, 
Serbia, Slovakia, Slovenia, Macedonia (former Yugoslav 
Republic of)
Eastern Europe (n=3) Belarus, Estonia (n=1, 0), Latvia, Lithuania, Moldova* (n=1, 
1), Russian Federation (n=1, 0), Ukraine
*Those for which data were available are marked with an asterisk.
A list of all references used for this analysis can be found in a web appendix 
(see http://www.anglia.ac.uk/verugbd).
The ‘n’ numbers indicate the number of studies from that country and following the 
comma, the number of new studies for that country included since the most recent 
Global Vision Database meta-analysis.
Table 2 Crude and age-standardised prevalence (%) of blindness and MSVI, mild VI and presbyopia in 2015 in high-income countries and in 
Eastern and Central Europe (all ages); 80% uncertainty intervals are given in brackets
blind MsVI Mild VI Presbyopia*
Crude prevalence
  Males 0.24 (0.10–0.42) 1.94 (0.86–3.28) 1.93 (0.62–3.68) – 
  Females 0.39 (0.16–0.68) 2.88 (1.29–4.84) 2.71 (0.92–5.04) – 
  All 0.32 (0.13–0.55) 2.42 (1.08–4.08) 2.33 (0.77–4.38) 18.94 (5.59–35.22)
Age-standardised prevalence
  Males 0.14 (0.06–0.24) 1.18 (0.51–2.00) 1.19 (0.37–2.29) – 
  Females 0.15 (0.06–0.27) 1.34 (0.58–2.30) 1.33 (0.42–2.54) – 
  All 0.15 (0.06–0.26) 1.27 (0.55–2.17) 1.27 (0.40–2.43) 18.58 (5.47–34.60)
*A gender breakdown for presbyopia is not presented due to data sparsity.
MSVI, moderate and severe vision impairment; VI, vision impairment.
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Division’s forecasts to derive the anticipated crude numbers and 
age-standardised prevalence estimates.14 Finally, for estimating 
the causal attribution to the blindness and vision impairment 
burden, we estimated the proportions of overall vision impair-
ment attributable to cataract, glaucoma, age-related macular 
degeneration (AMD), diabetic retinopathy, corneal opacity, 
trachoma, uncorrected refractive error and non-cause specific in 
1990–2015 by geographical region and year.3–5
resulTs
The super region of interest of our meta-analysis was the focus 
of 46 studies (table 1). All of the included studies were cross-sec-
tional population-based investigations, and the visual acuity data 
were ascertained through clinical examination. The majority of 
studies (41/46) included a broad age range in the adult population 
with a minimum age of 40 years. Out of the 46 studies, 28 were 
performed in urban regions, 4 studies in rural areas and 17 inves-
tigations were carried out in both, rural and urban regions. Six 
studies involved a Rapid Assessment methodology.
In the study super  region in 2015, the crude prevalence of 
blindness for all ages was 0.32% (80% UI 0.13–0.55), with a 
prevalence of 2.42% (80% UI 1.08%–4.08%) for MSVI and 
2.33% (80% UI 0.77–4.38) for mild vision impairment. The 
crude prevalence of presbyopia was 18.94% (5.59–35.22). 
These and age-standardised rates are given in table 2. Women 
were more likely to be blind or MSVI than men (high-income 
countries relative OR for blindness: 1.12 (95% UI 0.95–1.32); 
for MSVI: 1.15 (95% UI 1.05–1.25)).
The prevalence of blindness and of any kind of distance 
vision impairment in 2015 was slightly higher among women 
Figure 1 Ladder plot showing the age-standardised prevalence of blindness in men and women aged 50+ years for 2015. These are modelled 
estimates using prevalence figures applied to the individual populations of countries (point estimates with 80% uncertainty intervals are displayed).
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than among men across most of the regions (tables 2 and 3; 
figures 1, 2 and 3). As compared with the figures for 1990, the 
age-standardised prevalence of blindness for all ages and genders 
decreased from 0.26% (0.10–0.46) in 1990 to 0.15% (0.06–0.26) 
in 2015, and the age-standardised prevalence of MSVI decreased 
from 1.74% (0.76–2.94) in 1990 to 1.27% (0.55–2.17) in 2015.3 
These crude prevalence rates were used to calculate number of 
individuals in the subregions affected by blindness, MSVI and 
mild vision impairment, respectively: 70 000, 630 000 and 
610 000 in Australasia; 980 000, 7.46 million and 7.25 million 
in North America and 1.16 million, 9.61 million and 9.47 million 
in Western Europe (table 4).
Among those aged 50 years and older in the super region of 
high-income countries and Eastern and Central Europe, 6.72% 
(80% UI 2.99–11.33) were blind or vision impaired. The most 
common cause of all forms of vision impairment in this age 
group was uncorrected refractive error with a crude prevalence 
of 3.03% (80% UI 1.28%–5.3%). Ranked by crude prevalence 
in this age group, the next most common causes were cataract 
(1.07%; 80% UI 0.31–2.53), AMD (0.81%; 80% UI 0.09–2.80), 
glaucoma (0.33%; 80% UI 0.04–1.15) and diabetic retinopathy 
(0.28%; 80% UI 0.02–1.10). A detailed datasheet of cause-spe-
cific crude and age-standardised prevalence and number of 
people affected of blindness and MSVI for high-income countries 
and in Eastern and Central Europe by region in 5-year intervals 
from 1990 to 2020 is given in online supplementary appendix 
table 1 for all ages and in online supplementary appendix table 2 
for those aged 50 years and older.
Figure 2 Ladder plot showing the age-standardised prevalence of moderate and severe vision impairment in men and women aged 50+ years for 
2015. These are modelled estimates using prevalence figures applied to the individual populations of countries (point estimates with 80% uncertainty 
intervals are displayed).
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The top causes of blindness worldwide from 1990 to 2020 
are presented in table 5a–d.14 In 1990, cataract was the most 
frequent cause of blindness, followed by uncorrected refrac-
tive error, glaucoma, AMD, cornea-related diseases, trachoma 
and diabetic retinopathy (table 5a). This world ranking of top 
4 causes remained constant in 2015 (table 5c) and by 2020 
(table 5d).
Within the regions that comprise the super region of high-in-
come countries and Eastern and Central Europe, cataract was 
also the most common cause of blindness in 2015 (table 5c) 
ranging from 19.7% (Australasia) to 25.4% (Central Europe) 
of the blindness burden (vs 35.2% of world blindness burden). 
AMD was the second most common cause of blindness in all 
regions accounting for 15.4% (Western Europe) to 19.5% 
(Eastern Europe) of the blindness burden (vs 5.9% of world 
blindness burden), corresponding to a higher prevalence of 
more easily treated conditions in less developed countries. 
Within this super region, glaucoma was the third most common 
cause of blindness in all regions, accounting for 13.5%–14.3% 
of the blindness burden. It was followed by uncorrected refrac-
tive error that caused 13.0% to 13.1% of all blindness burden. 
Diabetic retinopathy accounted for 3.1% (Central Europe) to 
4.9% (Eastern Europe) of the blindness burden (vs 1.1% of world 
blindness burden). Cornea-related disorders accounted for 2.4% 
(North America, high income) to 3.6% (Central Europe) of the 
blindness burden, ranking sixth in all regions except for Central 
Europe where they surpassed diabetic retinopathy to rank fifth 
as a cause of blindness. The cause-specific proportion of blind-
ness rankings in this super region are expected to change by 
2020 with glaucoma becoming the third most common cause for 
Figure 3 Ladder plot showing the age-standardised prevalence of mild vision impairment in men and women aged 50+ years for 2015. These are 
modelled estimates using prevalence figures applied to the individual populations of countries (point estimates with 80% uncertainty intervals are 
displayed).
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blindness in all regions, whereas undercorrection of refractive 
error is expected to fall back to the fourth position (table 5d). 
Between 1990 and 2015, a decline in the proportion of blind-
ness due to cataract and cornea-related diseases was observed, 
whereas the proportion of diabetic retinopathy-related blindness 
increased.
The top causes of MSVI worldwide from 1990 to 2020 are 
presented in table 6a–d.6 In 1990, uncorrected refractive error 
was worldwide the most frequent cause of MSVI followed by 
cataract, AMD, glaucoma, corneal opacity, trachoma and diabetic 
retinopathy (table 6a). This world ranking of top 4 causes 
remained constant in 2015 (table 6c) and by 2020 (table 6d). At 
the lower end of the ranking list, diabetic retinopathy increased, 
and cornea-related disorders decreased in their ranking positions 
as causes for MSVI.
Within the regions that comprise the super region of high-in-
come countries and Eastern and Central Europe, uncorrected 
refractive error was by far the most common cause of MSVI in 
2015 (table 6c) ranging from 48.5% (Eastern Europe) to 49.6% 
(Western Europe) of the MSVI burden (vs 52.3% of world 
MSVI burden). Cataract was the second most common cause 
of MSVI in all regions and accounted for 14.1% (Australasia) 
to 18.2% (Central Europe) of the MSVI burden (vs 25.2% of 
world MSVI burden). Within this super region, AMD was the 
third most common cause of MSVI in all regions and accounted 
for 10.7%–13.4% of the MSVI burden (vs 4.4% of world MSVI 
burden). Glaucoma accounted for 3.6% (Western Europe) to 
4.1% (Eastern Europe) of the MSVI burden (vs 2.1% of world 
MSVI burden), whereas diabetic retinopathy accounted for 
3.1% (Central Europe) to 5.1% (Eastern Europe) for MSVI 
burden. Glaucoma was the fourth most common cause of MSVI 
in Central and Western Europe, whereas diabetic retinop-
athy was the fourth most common cause of MSVI in the Asia 
Pacific high-income region, Australasia, Eastern Europe and 
in the North America high-income region. The cause-specific 
proportion of MSVI rankings in this super region are expected 
to remain relatively constant to the year 2020 (table 6d), except 
for a slight increase for diabetic retinopathy in its proportion of 
MSVI burden.
Between 1990 and 2015, a decline in the proportion of cata-
ract MSVI and of cornea-related diseases associated MSVI was 
observed, whereas the proportion of MSVI due to diabetic reti-
nopathy increased.
dIsCussIon
This update, using an improved statistical model, provides 
prevalence data and numbers affected for this super region 
through 2015 using data from more data sources (n=46) 
than our previous meta-analysis (n=37) for 2010 estimates. 
This super region of high-income countries and for Eastern 
and Central Europe is home to 11.5%, 14.7% and 16.2% of 
the World’s blind, moderately and severely vision impaired 
and mild vision impaired people, respectively (table 4). Addi-
tionally, we estimate that 13.0% of the world’s population of 
presbyopes resides in this super region. By 2020, this contribu-
tion to the world’s vision impaired is expected to lessen slightly 
(10.8%, 13.9%, 15.5% and 11.9%, respectively). We estimate 
that 66.6 million people in this super region were unable to see 
6/12 in the better eye in 2015, and that this number will rise to 
69.0 million by 2020.
Within this super region, cataract was the most common 
cause of blindness in 2015, followed by AMD. The contribu-
tion of glaucoma to blindness decreased between 1990 and T
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2015 (table 5). Only few studies have assessed the incidence 
of glaucoma blindness over the years of interest. The Olmsted 
County study suggested that incidence of glaucoma blindness 
was decreasing, since the 20-year probability of glaucoma-re-
lated blindness and the incidence of blindness due to open-angle 
glaucoma in at least one eye decreased from 1965 to 2009.15
Despite the ageing of the population, AMD has decreased in 
its percentage of causes for blindness during the study period. 
The success of previously introduced clinical therapies of exuda-
tive AMD, that is, the intravitreal injection of antivascular endo-
thelial growth factor drugs,16–18 may have reduced the extent of 
vision loss from AMD to a level more favourable than 3/60.
The increasing importance of diabetic retinopathy as a cause 
for vision loss likely reflects the increasing prevalence of diabetes 
mellitus in the general population and the ageing of the popu-
lation so that individuals with diabetes live to an age at which 
ocular complications of their systemic disease are experienced.19
Limitations of our study should be mentioned. First, there 
were some, mostly minor, differences in causal proportions for 
1990 and 2010 in these new estimates compared with what we 
published for those years previously.3 This is because the model 
has been improved, the sources have increased and the nature 
of the new sources has changed. Second, rapid assessment 
surveys often only contributed data on presenting visual acuity 
and, in some cases, data on best-corrected visual acuity data, 
usually measured though a pinhole. With these surveys, only 
data relating to cataract and uncorrected refractive error were 
included in the model as causes for vision impairment. Third, 
the proportions of best-corrected vision attributable to causes 
other than cataract, AMD, glaucoma or trachoma (ie, diabetic 
retinopathy and corneal diseases) were calculated with data from 
surveys that had assessed at least cataract and AMD. Fourth, 
despite extensive data seeking, data were not available for many 
countries and years, were reported using sometimes incompa-
rable definitions of vision impairment or were representative of 
a subnational or community area only. Fifth, a major part of the 
causes of blindness and MSVI has remained uncovered and has 
been included as ‘other causes’ in the analysis. In this updated 
meta-analysis, we report that ‘other causes’ accounted for about 
23% worldwide of the causes of blindness, whereas our previ-
ously published 2010 estimate was 28%.4 While the proportion 
in the non-specific ‘other’ category is in the present report, many 
causes remain unspecified as a result of logistically imposed 
limitations of the data in the meta-analysis. Sixth, most popu-
lation-based studies of eye disease did not include individuals 
living in nursing homes, whereas there were reports in high-in-
come countries of double the prevalence of vision loss. Seventh, 
the basic studies used different definitions of the diseases, in 
particular for glaucoma.20 Eighth, eyes with vision loss often had 
several diseases, so that it might have been difficult to decide 
which one of the diseases was the factor contributing most to the 
vision loss. Finally, caution should be exercised in interpretation 
of projections to 2020 by cause. These projections assumed that 
the United Nations population projections for the future were 
correct, and the covariates that we used in our model for access 
to healthcare and literacy which have not been modelled into the 
future will remain unchanged after 2015. Thus, the projections 
to some extent reflect what would be if improvements are not 
made in response to this and other reports.
The results of this surveillance exercise have important impli-
cations for future health policy. The burden of uncorrected 
refractive error contributes to almost half of the moderate and 
severe vision impairment burden. Identification of remediation 
of barriers to adults seeking refractive error correction needs to T
ab
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be a priority both because of this disease burden and because 
this is often the route in high-income countries that leads to 
diagnosis of other coexistent ocular pathologies, such as cataract 
which also remains a substantial contributor to vision impair-
ment. Efforts to reduce the backlog of patients requiring cata-
ract operations should be prioritised. Heightening awareness 
of these causes, most of which are relatively simple to address, 
particularly in economically developed countries will undoubt-
edly assist, yet within these populations, substantial inequity 
in eye care access exists which needs to be better understood. 
Screening for glaucoma may be of benefit if targeting high-risk 
groups in populations.21 Vision impairment from both glaucoma 
and forms of AMD may be arrested or mitigated by timely inter-
vention, and therefore, awareness of these diseases and detec-
tion and treatment strategies need to be prioritised. Although 
diabetic retinopathy was a less common cause of vision impair-
ment, its contribution is rising. Several high-income countries 
have effective diabetic retinopathy screening programmes; 
programmes such as this should be actively encouraged. A 
broader data stream regarding the burden of visual impairment 
and the causes thereof also is needed to improve the accuracy of 
ongoing surveillance efforts to inform health policy.
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